#1 PRESCRIBED MIGRAINE TREATMENT IN ITS CLASS SINCE 8/6/21*

For the acute treatment of migraine and the preventive treatment of episodic migraine in adults

You have the power to help patients take control of their migraine treatment

Nurtec® ODT (rimegepant) orally disintegrating tablets 75 mg

Approximately 40 million people have migraine, a condition that is underdiagnosed and undertreated[1,2]

- Migraine is one of the top 10 reasons people visit their primary care provider (PCP)[3]
- Migraine is the leading cause of disability among men and women between the ages of 15 and 49[4]
- Migraine can be an immense burden on patients' personal and professional lives[4]
- ≈1/3 of patients seen in PCP offices for any reason have migraine[3]
- Average wait time to see a headache specialist can be 15 months[5]
- Suboptimal acute treatment of migraine is associated with risk of disease progression[6]

Nurtec ODT is an orally dissolving calcitonin gene-related peptide (CGRP) receptor antagonist[7] and the #1 prescribed treatment in its class*

- **One 75 mg tablet as needed to help stop a migraine attack.[7]**
- **One 75 mg tablet every other day to help prevent migraine attacks.[7]**
- The maximum dose in a 24-hour period is 75 mg. The safety of using more than 18 doses in a 30-day period has not been established.[7]

*Per IQVIA as oral brand in class (oral CGRP receptor antagonists): number one prescribed and number one in new prescriptions, since 8/6/21. Data current as of 1/10/23.

Why is it so important for a patient to know their migraine triggers?

Because many migraine triggers are predictable, but also unavoidable.[8]

COMMON TRIGGERS[8]

SELECT IMPORTANT SAFETY INFORMATION

Contraindications: Hypersensitivity to Nurtec ODT or any of its components.
Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash and can occur days after administration.
Please see additional Important Safety Information on the next page and click here for full Prescribing Information.

Nurtec® ODT (rimegepant)
orally disintegrating tablets 75 mg

Nurtec ODT is the only medication proven to treat and prevent migraine attacks all in one[7,9]

ACUTE TREATMENT

Superiority over placebo at 2 hours post-dose[7,9,‡]



MBS=most bothersome symptom; predefined as photophobia, phonophobia, or nausea

‡Patients using rescue medications at or before the assessment and patients not providing data were classified as treatment failures.[9]

PREVENTIVE TREATMENT

Reduction in monthly migraine days[7,¶]

Primary endpoint at weeks 9 through 12



Baseline MMDs during the 4-week observation period were 10.3 for rimegepant-treated subjects and 9.9 for placebo-treated subjects.

¶Analyzed using a generalized linear mixed-effects model with treatment group, preventive migraine medication use at randomization, study month, and month-by-treatment group interaction as fixed effects and participant as random effect.[10]

The clinical studies

ACUTE STUDY

For the acute treatment of migraine with or without aura in adults, Nurtec ODT was evaluated in a multi-center, double-blind, randomized, placebo-controlled study in which 1466 patients were randomized to Nurtec ODT (n=732) or placebo (n=734) and 1351 patients were evaluated for efficacy (n=669; n=682 respectively). The co-primary endpoints at 2 hours for Nurtec ODT vs placebo were pain freedom and freedom from most bothersome symptom; predefined as photophobia, phonophobia, or nausea.[7]

PREVENTIVE STUDY

For the preventive treatment of episodic migraine in adults, rimegepant 75 mg every other day was evaluated in a multi-center, double-blind, randomized, placebo-controlled study in which 747 patients were randomized to rimegepant 75 mg (n=373) or placebo (n=374) and 695 patients were evaluated for efficacy (n=348; n=347 respectively). The primary endpoint was change from baseline in the mean number of MMDs during weeks 9 through 12.[7]

SELECT IMPORTANT SAFETY INFORMATION

Adverse Reactions: The most common adverse reactions were nausea (2.7% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo) and abdominal pain/dyspepsia (2.4% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.

Please see additional Important Safety Information on the next page and click here for full Prescribing Information.

Nurtec® ODT (rimegepant) orally disintegrating tablets 75 mg

More than 286 million individuals have access to Nurtec ODT across all channels**

Nurtec ODT leads in access for the oral CGRP receptor antagonist category**

Coverage for **96%** of commercially insured lives**

Eligible, commercially insured patients may **pay as little as $0** per month with the Nurtec ODT copay card. Terms and conditions apply.††

Learn about the benefits of a one-stop support program for your patients: **Nurtec® OneSource**‡‡

**Managed Markets Insights & Technology LLC as of 1/17/23.

†† Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico. **The offer will be accepted only at participating pharmacies. This offer is not health insurance.** No membership fees apply. Pfizer reserves the right to rescind, revoke, or amend this offer without notice. For full terms and conditions or any questions, please call 1-800-761-1568, visit nurtec.com/savings#terms-and-conditions, or write to Pfizer Inc. at PO Box 29387, Mission, KS 66201.

‡‡ Getting started: No enrollment forms, just ePrescribe and select ASPN Pharmacies in your EHR (ASPN Pharmacies LLC, 290 West Mount Pleasant Ave, Livingston, NJ 07039. NPI: 1538590690). Prescriptions can also be faxed to ASPN Pharmacies at 1-877-371-2213.

One 75 mg dosage strength puts the power to treat and prevent in your patients' hands[7]

EXAMPLE FOR ACUTE TREATMENT

Nurtec ODT:
One 75 mg tablet as needed[7]

DISP:
One 8-pack for 30 days



Additional prescribing considerations[7]:
- 24-hour max: one 75 mg ODT
- 30-day max: 18 doses

EXAMPLE FOR PREVENTIVE TREATMENT

Nurtec ODT:
One 75 mg tablet every other day[7]

DISP:
Two 8-packs for 30 days

Prescribe for your patients' individual needs with one or two 8-packs

For more information about Nurtec ODT 75 mg or to **request samples**, please contact a **Pfizer representative** or scan the **QR code**

SELECT IMPORTANT SAFETY INFORMATION

Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, or strong or moderate inducers of CYP3A. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4 or potent inhibitors of P-gp.

Please see additional Important Safety Information on the next page and click here for full Prescribing Information.

IMPORTANT SAFETY INFORMATION

Contraindications: Hypersensitivity to Nurtec ODT or any of its components.

Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash and can occur days after administration.

Adverse Reactions: The most common adverse reactions were nausea (2.7% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo) and abdominal pain/dyspepsia (2.4% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.

Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, or strong or moderate inducers of CYP3A. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4 or potent inhibitors of P-gp.

Use in Specific Populations: *Pregnancy:* It is not known if Nurtec ODT can harm an unborn baby. *Lactation:* The transfer of rimegepant into breastmilk is low (<1%). *Hepatic impairment:* Avoid use of Nurtec ODT in persons with severe hepatic impairment. *Renal impairment:* Avoid use in patients with end-stage renal disease.

You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (U.S. only). If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

INDICATIONS

Nurtec ODT is indicated in adults for the:

- acute treatment of migraine with or without aura
- preventive treatment of episodic migraine

Please click here for full Prescribing Information.

Price disclosure information for prescribers is available here.

References: 1. Buse DC, Marianna S, Yugrakh MD, et al. Burden of Illness Among People with Migraine and ≥4 Monthly Headache Days While Using Acute and/or Preventive Prescription Medications for Migraine. *J Manag Care Spec Pharm*. 2020;26(10):1334-43. **2.** American Headache Foundation. Migraine 101: What you should know. Accessed April 11, 2023. https://americanmigrainefoundation.org/migraine-101/ **3.** Martin V, Feoktistov A, Solomon G. A rational approach to migraine diagnosis and management in primary care. *Ann Med*. 2021;53(1):1969-1980. doi: 10.1080/07853890.2021.1995626 **4.** Guerrero A, Negro A, Ryvlin P, et al. Need of guidance in disabling and chronic migraine identification in the primary care setting, results from the european MyLife anamnesis study. *BMC Fam Pract*. 2021;22(54):1-9. https://doi.org/10.1186/s12875-021-01402-2. **5.** National Headache Foundation. Wait times for headache care remain long. February 20, 2018. Accessed March 16, 2023. https://headaches.org/wait-times-headache-care-remain-long/ **6.** Lipton RB, Fanning KM, Serrano D, et al. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. *Neurol*. 2015;84:688-695. **7.** Nurtec ODT. Package insert. Pfizer Inc. **8.** Health Union, LLC. *Migraine in America 2021*. Health Union, LLC; 2020. **9**. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablets for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. *Lancet*. 2019;394(10200):737-745. doi:10.1016/S0140-6736(19)31606-X **10.** Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for the preventive treatment of migraine: a phase 2/3, randomized, double-blind, placebo-controlled trial. *Lancet*. 2021;397(10268):51-60. doi: 10.1016/SO140-6736(20)32544-7

Intended for use by U.S. healthcare professionals only.

March 2023. PP-NNT-USA-0343.

Pfizer | Nurtec® ODT (rimegepant) orally disintegrating tablets 75 mg